The HM3 has shown excellent long-term outcomes ten years after implantation, with no technical malfunctions and a low incidence of hemocompatibility-related adverse events. This study highlights the strong performance of assist devices and excellent outcomes for heart failure patients, especially when LVADs are timely and appropriately used in selected patients.
Hanke et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: